Intravenous secretin for autism: over 900 children, no evidence of benefit

In one sentence

This Cochrane review found no evidence that intravenous secretin helps autistic children, even after trials involving more than 900 participants.

What the researchers did

Secretin is a hormone linked to the digestive system. In the late 1990s, it was suddenly promoted as a possible treatment for autism after anecdotal reports suggested dramatic improvements in some children. Those early stories drew a great deal of public attention, and many families pursued secretin before solid evidence existed.

The Cochrane reviewers asked a straightforward question: when secretin is tested properly in randomised, placebo-controlled trials, does it improve the main features of autism spectrum disorder?

To answer that, they gathered studies in which children were randomly assigned to receive intravenous secretin or a placebo. The review included 16 trials with more than 900 children overall. That is an important strength: unlike many autism interventions that are studied only in small groups, secretin had already been tested repeatedly and across a fairly large number of participants.

The researchers looked at outcomes that matter most in autism research, including social interaction, communication, and restricted or repetitive behaviour. They also considered whether single doses and repeated doses made any difference.

What they found

The review found no evidence that intravenous secretin improved the core features of autism.

This was true across the main areas families usually hope to change: social connection, communication, and repetitive patterns of behaviour. The lack of benefit was seen whether children received a single dose or multiple doses. In other words, the overall message did not depend on one unusual trial or one specific dosing plan.

That consistency matters. Sometimes a treatment looks disappointing in one study but still seems worth pursuing because the evidence is mixed. Here, the problem was not mixed evidence. It was that many studies had already been done, and together they still did not show meaningful benefit.

Because of that, the review authors reached a stronger conclusion than "more study is needed." They wrote that secretin should not currently be recommended or given as a treatment for autism spectrum disorder.

The review did leave a narrow door open for future research, but only if convincing new biological evidence were found to explain why secretin might help some subgroup of autistic children. Without that kind of new evidence, further testing would be hard to justify.

What this means for families and therapists

For families, this review is a reminder that early excitement around a treatment is not the same as proof. Secretin became popular because of hopeful stories, but when researchers tested it carefully in large numbers of children, the results did not support those hopes.

That is important because unproven treatments can cost money, time, and emotional energy. They can also distract families from supports that are better studied or more clearly matched to a child's needs.

For therapists and clinicians, the review provides a clear evidence-based message: intravenous secretin should not be described as an effective intervention for autism's core features. A treatment that has been studied in more than 900 children without showing benefit has already had a serious chance to prove itself.

Limitations and what we don't know yet

Even though this review was much stronger than many reviews in this area, it still cannot prove that secretin has absolutely no effect in every possible child. Science rarely works in absolutes.

But the available evidence is already extensive enough to make the practical conclusion clear. If secretin does have any benefit, it has not shown up in the outcomes that matter most, across many trials and many children.

Future research would only make sense if there were strong new evidence suggesting a specific mechanism, a clearly defined subgroup, or a new reason to think secretin works differently than these trials suggested. Until then, it should not be recommended as an autism treatment.

---

This is a simplified summary of Intravenous secretin for autism spectrum disorders (ASD) by Williams K, Wray J.A, Wheeler D.M, Cochrane Database of Systematic Reviews (2012).

Source license: CC-BY-NC-4.0.

This is not medical advice. Please consult a qualified healthcare professional before making therapy decisions.